Hetero received approval from The Drug Controller General of India (DCGI) to manufacture and market the Molnupiravir capsules 200 mg (Movfor) to cease the pandemic prevailing all over.
Movfor is an investigational, orally bioavailable medicine indicated for restricted emergency use in India to treat adult patients affected with COVID 19, with SpO2>93%, or who have a high risk of disease progression or hospitalization.
Movfor 200 MG Capsules has its active agent as Molnupiravir which is a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses, including SARS-CoV2, that causes COVID 19. It is active in several models of SARS-CoV-2, including for prophylaxis, treatment and prevention of transmission, as well as SARS-CoV-1 and MERS (Middle East respiratory syndrome, a viral respiratory disease caused by a novel coronavirus).
Availability: Movfor 200 MG Capsules is available with Hetero Healthcare now in a 40 capsule pack (200 MG per capsule). We are the manufacturers, bulk suppliers and distributors of the medicine across India to combat Corona.